Saturday 17 October 2026
Export NTRA’s income statement to Excel — free account
Natera, Inc.
NTRA Healthcare Diagnostics & Research
Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 36.5%, free cash flow fell 174.0% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
391.98
12.81
−3.16%
Follow NTRA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
14.37 | 11.32 | 13.58 | 10.43 | |
P/FCF ratio |
461.93 | 270.78 | 287.05 | 208.20 | |
P/Operating CF |
709.82 | 704.46 | 423.90 | 371.85 | |
P/B ratio |
21.35 | 15.95 | 18.29 | 17.64 | |
Price to Tangible BV |
29.46 | 22.36 | 26.15 | 17.79 | |
EV/Sales |
14.10 | 11.03 | 13.27 | 10.11 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
167.23 | 130.69 | 142.18 | 110.18 | |
EV/FCF |
453.32 | 263.88 | 280.55 | 201.83 | |
Quick Ratio |
2.74 | 2.70 | 3.11 | 3.01 | |
Current Ratio |
3.00 | 2.96 | 3.39 | 3.27 | |
Net Debt/EBITDA |
18.52 | 13.75 | 114.60 | 11.02 | |
Debt/Assets |
3.02% | 3.07% | 3.35% | 4.41% | |
Debt/Equity |
0.04 | 0.05 | 0.05 | 0.06 | |
Asset Turnover |
1.23 | 1.15 | 1.14 | 1.24 | |
Operating CF/Net income |
(0.82) | (0.47) | 1.56 | (0.68) | |
Capex/Depreciation |
(2.99) | (1.09) | (2.56) | (2.17) | |
Interest Coverage |
(85.16) | (104.84) | (23.02) | (93.37) | |
Research and Development Expense of Revenue |
30.30% | 30.25% | 26.33% | 29.28% | |
Selling, General and Administrative Expense of Revenue |
43.47% | 47.07% | 43.77% | 52.10% | |
Intangible Assets out of Total Assets |
0.19 | 0.19 | 0.21 | 0.00 | |
Share Based Compensation of Revenue |
13.70% | 13.65% | 13.91% | 15.31% | |
Graham Net Nets |
0.02 | 0.03 | 0.03 | 0.04 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(0.50%) | (0.82%) | (0.67%) | (1.42%) | |
Free Cash Flow Yield |
0.22% | 0.37% | 0.35% | 0.48% | |
Revenue per Share |
5.25 | 4.92 | 4.87 | 4.32 | |
Operating CF per Share |
0.38 | 0.28 | 0.54 | 0.43 | |
Capex per Share |
(0.44) | (0.16) | (0.26) | (0.16) | |
Free Cash Flow per Share |
(0.06) | 0.13 | 0.28 | 0.27 | |
Cash per Share |
7.62 | 7.69 | 7.87 | 7.60 | |
Shareholders Equity per Share |
12.71 | 12.54 | 12.52 | 9.13 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
12.71 | 12.54 | 12.52 | 9.13 | |
Free Cash Flow |
(8.64) | 18.03 | 37.82 | 36.98 | |
Working Capital |
1,105.75 | 1,093.56 | 1,055.71 | 1,005.31 | |
Capital Expenditures |
(63.43) | (22.14) | (36.07) | (22.40) | |
Net Current Asset Value |
822.95 | 811.43 | 811.01 | 878.03 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.08 | 0.03 | 0.05 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
365.60 | 367.91 | 305.35 | 296.63 | |
Average Payables |
56.02 | 50.82 | 34.04 | 37.17 | |
Average Inventory |
67.31 | 60.54 | 56.59 | 56.68 | |
Average Assets |
2,207.28 | 2,173.38 | 2,029.54 | 1,706.21 | |
Average Common Equity |
1,533.84 | 1,506.85 | 1,453.92 | 1,065.36 |
Columns are period end dates